Method for establishing non-human primate autoimmune cerebrospinal meningitis model and application of model

A meningococcal and autoimmune technology, applied in the field of non-human primate autoimmune meningitis model establishment, can solve the problems of long induction method, inability to apply the model, and large individual rhesus monkeys, and achieve shortening time. Induction period, strict quality control, small effect of animals

Inactive Publication Date: 2015-07-08
上海浦灵生物科技有限公司
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the disadvantages of this model are: 1. Single onset; 2. The induction method takes a long time; 3. Rhesus monkeys are relatively large; 4. More subjective symptom evaluation criteria are adopted
These shortcomings prevent the model from being applied in scientific research, drug evaluation, and industrial practice

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for establishing non-human primate autoimmune cerebrospinal meningitis model and application of model
  • Method for establishing non-human primate autoimmune cerebrospinal meningitis model and application of model
  • Method for establishing non-human primate autoimmune cerebrospinal meningitis model and application of model

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0036] Experimental animals: 4 cynomolgus monkeys (Macaca fascicularis, male, 4 years old, weighing 3-5 kg);

[0037] Main reagents: Complete Freund adjuvant (CFA); MOG34-56 peptide;

[0038] Preparation of immune-inducing emulsion: MOG34-56 was dissolved in physiological saline (NS) and emulsified with an equal volume of CFA at 4°C for 5 minutes;

[0039] experimental method:

[0040] The prepared MOG-CFA emulsion was injected into the skin of cynomolgus monkey animals at 10 injection sites, and each monkey was injected with 1 ml;

[0041] And on the 7th day after the first injection (immunization), MOG-CFA emulsion was prepared according to the same method, and the second immunization injection was carried out according to the same dose and method;

[0042] Experimental results:

[0043] According to the observation, scoring, brain magnetic resonance (MRI) scan, and pathological sections of brain tissue after the immunization injection of monkey animals: all 4 cynomolgus...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a method for establishing a non-human primate autoimmune cerebrospinal meningitis model and the application of the model. The specific technical scheme comprises the following steps; a machin is selected as the non-human primate experimental animals; MOG34-56(100Mug/ml) is prepared into an emulsion (MOG CFA=1; 1); after the experimental machin is anesthetized, the machin is intradermally injected with 1ml of prepared emulsion at 10 injection points; on the seventh day after the first injection, an MOG-CFA emulsion is prepared by use of the same method, and the second immune injection is performed at the same dosage and by use of the same method; the experimental autoimmune cerebrospinal meningitis model established by use of the method has the clinical characters of remission-relapse, and can be widely used to the related field of disseminated sclerosis diseases. Compared with the existing rhesus method and model, the method and the model also have the characteristics of short induction period, low cost, rich monkey resources and the like, and also have the application value which cannot be realized by rodent models.

Description

technical field [0001] The invention relates to the establishment of a non-human primate disease model, in particular to a method for establishing a non-human primate autoimmune encephalomyelitis model and its application. Background technique [0002] Experimental autoimmune encephalomyelitis (EAE) is induced by isotype, allotype, and xenogeneic encephalitogenic antigens, produced in experimentally sensitive animals, mediated by cellular immune responses, and expressed in the central nervous system. A delayed-type allergic autoimmune disease characterized by white matter demyelination in the central nervous system (CNS), and its immune pathogenesis and lesions are similar to multiple sclerosis (MS) in humans Ideal model for sexual sclerosis disease. [0003] Current experimental autoimmune encephalomyelitis (EAE) models are usually established in rodents. Since rodents are far from humans in evolutionary relationship, practice has shown that the experimental results gener...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61D7/00
CPCA61D7/00
Inventor 倪佳王松邓继林刘俊娥张红宋之战
Owner 上海浦灵生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap